Predictive Value of the Serum Matrix Metalloproteinase-9 Level on Hepatic Encephalopathy in Patients with Chronic Liver Disease.
Ann Clin Lab Sci
; 51(5): 713-720, 2021 Sep.
Article
em En
| MEDLINE
| ID: mdl-34686515
ABSTRACT
BACKGROUND:
Early diagnosis of hepatic encephalopathy (HE) in chronic liver disease (CLD) is difficult clinically.OBJECTIVE:
The aim of this study was to evaluate whether serum matrix metalloproteinase-9 (MMP-9) levels could identify early HE in patients with CLD.METHODS:
Serum MMP-9 levels in 1,187 patients with CLD were measured at baseline. A total of 1,187 patients with CLD were followed for a mean of 48 months (range 4-50). The association between MMP-9 and the risk of HE was evaluated by logistic regression analysis and Cox regression analysis.RESULTS:
Patients with higher serum MMP-9 levels had higher rates of HE history and HE events during follow-up (all P<0.001). The multivariate logistic regression analysis revealed that MMP-9 (OR=2.84, 95% CI 1.63-7.11, P=0.004) was independently associated with HE history, with an increased grade of aggravation on liver fibrosis at baseline. Multivariate Cox proportional hazard analysis revealed that MMP-9 (HR=2.21, 95% CI 1.09-5.02, P<0.001) was an independent predictor for HE events by sensitivity analysis. The Kaplan-Meier analysis demonstrated that patients with MMP-9 above the median value (176.2 mg/d) had a higher rate of new HE events than patients who had MMP-9 levels below the median value (P<0.001).CONCLUSIONS:
Elevated serum RBP4 levels were associated with a higher risk of HE events during follow-up. These results may suggest that serum MMP-9 has good predictive value for detecting HE in patients with CLD, which provides some clinical reference value to clinicians for the early diagnosis of HE.Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Encefalopatia Hepática
/
Metaloproteinase 9 da Matriz
/
Doença Hepática Terminal
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article